Diabetes Mellitus in Coronary Artery Surgery: Therapeutic Strategies in the Light of Recent Studies

Abstract

Advances in percutaneous coronary revascularization have meant that, increasingly, patients with multivessel diseases are initially treated with the methods of interventional cardiology. Ongoing studies involving new stent coatings and optimized anti-thrombotic therapies could help to lower future restenosis rates and improve the success rate of stenting. Thrombocyte glycoprotein IIb/IIIa receptor blockers have already been shown to reduce the rate of acute PTCA complications in high-risk patients and could have a sustained impact on the long-term prognoses for PTCA patients. However, for diabetic patients with coronary multivessel diseases, coronary artery bypass grafting using arterial grafts as the initial revascularization method must be given preference over other therapy methods. Consequently, this group of patients is bound to grow in importance in cardiac surgery. The advances made in percutaneous coronary revascularization and in coronary surgery call for further prospective, controlled, randomized clinical studies in order to establish the best possible treatment strategy for patients with diabetes. It should be noted, however, that the therapeutic effect of myocardial revascularization is generally limited to individual coronary-arterial segments, whereas the pathological process of atherosclerosis is rather diffuse. The surgical strategy should therefore be seen as part of an overall strategy which encompasses other forms of treatment (e.g. intensive efforts to improve control of blood glucose level, blood pressure, and cholesterol level) in order to arrest the general progression of the disease and to reduce the risk of myocardial infarction and death.

Diabetes mellitus - coronary artery disease - coronary artery bypass grafting - mortality - myocardial infarction - risk factors

References

• 1 Stamler J, Vaccaro O, Neaton J D, Wentworth D. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the multiple risk factor intervention trial.  Diabetes Care. 1993;  16 434-444
• 2 Lowe L P, Liu K, Greenland O, Metzger B E, Dyer A R, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men.  Diabetes Care. 1997;  20 163-169
• 3 Harris M I, Hadden W C, Knowler W C, Bennet P H. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20 - 74 years.  Diabetes. 1987;  36 523-534
• 4 Kannel W B, McGee D L. Diabetes and cardiovascular risk factors: the Framingham Study.  Circulation. 1979;  59 8-13
• 5 Cohen Y, Raz I, Merin G, Mozes B. Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus.  Am J Cardiol. 1998;  81 7-11
• 6 Morris J J, Smith L R, Jones R H. et al . Influence of diabetes and mammary artery grafting on survival after coronary bypass.  Circulation. 1991;  84 275-284
• 7 Weintraub W S, Wenger N K, Jones E L, Craver J M, Guyton R A. Changing clinical characteristics of coronary surgery patients. Differences between men and women.  Circulation. 1993;  88 79-86
• 8 Jacoby R M, Nesto R W. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis.  J Am Coll Cardiol. 1992;  20 736-744
• 9 Karlson B W, Herlitz J, Hjalmarson A. Prognosis of acute myocardial infarction in diabetic and non-diabetic patients.  Diabet Med. 1993;  10 449-454
• 10 Zarich S, Waxman S, Freeman R T, Mittleman M, Hegarty P, Nesto R W. Effect of autonomic nervous system dysfunction on the circadian pattern of myocardial ischemia in diabetes mellitus.  J Am Coll Cardiol. 1994;  24 956-962
• 11 Nasher Jr P J, Brown R E, Oskarsson H, Winniford M D, Rossen J D. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus.  Circulation. 1995;  91 635-640
• 12 Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali J R. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function.  Diabetes. 1993;  42 1017-1025
• 13 Huszka M, Kaplar M, Rejto L. et al . The association of reduced endothelium derived relaxing factor-NO production with endothelial damage and increased in-vivo platelet activation in patients with diabetes mellitus.  Thromb Res. 1997;  86 173-180
• 14 Diederich D, Skopec J, Diederich A, Dai F X. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals.  Am J Physiol. 1994;  266 H1153-1161
• 15 Mayhan W G. Impairment of endothelium-dependent dilatation of cerebral arterioles during diabetes mellitus.  Am J Physiol. 1989;  256 H621-625
• 16 Tesfamariam B, Jakubowski J A, Cohen R A. Contraction of diabetic rabbit aorta caused by endothelium-derived PGH₂-TXA₂.  Am J Physiol. 1989;  257 H1327-1333
• 17 Lee T S, Mac Gregor L C, Fluharty S J, King G L. Differential regulation of protein kinase C and (Na, K)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells.  J Clin Invest. 1989;  83 90-94
• 18 Gawler D, Milligan G, Spiegel A M, Unson C G, Houslay M D. Abolition of the expression of inhibitory guanine nucleotide regulatory protein G1 activity in diabetes.  Nature. 1987;  327 229-232
• 19 Abaci A, Oguzhan A, Kahraman S. et al . Effect of diabetes mellitus on formation of coronary collateral vessels.  Circulation. 1999;  99 2239-2242
• 20 Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study.  Circulation. 1999;  99 2626-2632
• 21 Malmberg K, Herlitz J, Hjalmarsson A, Ryden L. Effects of metropolol on mortality and late infarction in diabetics with suspected acute myocardial infarction: retrospective data from two large scale studies.  Eur Heart J. 1989;  10 423-428
• 22 The Bypass Angioplasty Revascularization Investigation (BARI) Investigators . Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation.  Circulation. 1997;  96 1761-1769
• 23 Abizaid A, Kornowski R, Mintz G. et al . The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation.  J Am Coll Cardiol. 1998;  32 584-589
• 24 Thourani V H, Weintraub W S, Stein B. et al . Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting.  Ann Thorac Surg. 1999;  67 1045-1052
• 25 The Bypass Angioplasty Revascularization Investigation (BARI) Investigators . Comparison of bypass surgery with angioplasty in patients with multivessel disease.  N Engl J Med. 1996;  335 217-225
• 26 Lawrie G M, Morris Jr G C, Glaeser D H. Influence of diabetes mellitus on the results of coronary bypass surgery. Follow-up of 122 diabetic patients ten to 15 years after surgery.  JAMA. 1986;  256 2967-2971
• 27 The Bypass Angioplasty Revascularization Investigation (BARI) Investigators . Protocoll for the bypass angioplasty revascularization investigation.  Circulation. 1991;  84 V1-V27
• 28 Brooks M M, Jones R H, Bach R G. et al . Predictors of mortality and mortality from cardiac causes in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial and registry.  Circulation. 2000;  101 2682-2689
• 29 The Bypass Angioplasty Revascularization Investigation (BARI) Investigators . Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status.  J Am Coll Cardiol. 2000;  35 1130-1133
• 30 Niles N W, McGrath P D, Malenka D. et al . Northern New England Cardiovascular Disease Study Group. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous revascularization: results of a large regional prospective study.  J Am Coll Cardiol. 2001;  37 1016-1018
• 31 Abizaid A, Costa M A, Centemero M. et al . Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients. Insights from the Arterial Revascularization Therapy Study (ARTS) trial.  Circulation. 2001;  104 533-538
• 32 Serruys P W, Unger F, Sousa J E. et al . Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.  N Engl J Med. 2001;  344 1117-1124
• 33 Marso S P, Lincoff A M, Ellis S G. et al . for the EPISTENT Investigators. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy.  Circulation. 1999;  100 2477-2484
• 34 Kuntz R E. Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma.  Circulation. 1999;  99 847-851
• 35 Detre K M, Lombardero M S, Brooks M M. et al . The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction.  N Engl J Med. 2000;  342 989-997
• 36 Alderman E L. Late benefit of coronary surgery on mortality from myocardial infarction.  Circulation. 1991;  83 1087-1089
• 37 Peduzzi P, Detre K, Murphy M L, Thomsen J, Hultgren H, Takaro T. Ten-year incidence of myocardial infarction and prognosis after infarction. Department of Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery.  Circulation. 1991;  83 747-755
• 38 Grossi E A, Esposito R, Harris L J. et al . Sternal wound infections and use of internal mammary artery grafts.  J Thorac Cardiovasc Surg. 1991;  102 342-346 discussion 346-347
• 39 He G W, Ryan W H, Acuff T E. et al . Risk factors for operative mortality and sternal wound infection in bilateral internal mammary artery grafting.  J Thorac Cardiovasc Surg. 1994;  107 196-202
• 40 Calafiore A M, Vitolla G, Iaco A L. et al . Bilateral internal mammary artery grafting: midterm results of pedicled versus skeletonized conduits.  Ann Thorac Surg. 1999;  67 1637-1642
• 41 Wendler O, Hennen B, Demertzis S. et al . Complete arterial revascularization in multivessel coronary artery disease with 2 conduits (skeletonized grafts and T grafts).  Circulation. 2000;  102 79III-83III
• 42 Borger M A, Cohen G, Buth K J. et al . Multiple arterial grafts. Radial versus right internal thoracic arteries.  Circulation. 1998;  98 II7-13 discussion II13-14
• 43 Stewart R D, Campos C T, Jennings B, Lollis S S, Levitsky S, Lahey S J. Predictors of 30-day hospital readmission after coronary artery bypass.  Ann Thorac Surg. 2000;  70 169-174
• 44 Ennker J, Rehm I, Horst P, Hausmann H, Hetzer R. HbA1c als Infektions-Prädiktor in der Koronarchirurgie bei Patienten mit Diabetes mellitus.  Thorac Cardiovasc Surg. 1994;  42 50
• 45 Braxton J H, Marrin C AS, McGrath P D. et al . Mediastinitis and long-term survival after coronary artery bypass graft surgery.  Ann Thorac Surg. 2000;  70 2004-2007
• 46 Zerr K J, Furnary A P, Grunkemeier G L. et al . Glucose control lowers the risk of wound infection in diabetics after open heart operation.  Ann Thorac Surg. 1997;  63 356-361
• 47 Furnary A P, Zerr K J, Grunkemeier G L, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures.  Ann Thorac Surg. 1999;  67 352-360
• 48 Hennessey P J, Black C T, Andrassy R J. Nonenzymatic glycosylation of immunoglobulin G impairs complement fixation.  J Parenter Enter Nutr. 1991;  15 60-64
• 49 Black C T, Hennessey P J, Andrassy R J. Short-term hyperglycemia depresses immunity through nonenzymatic glycosylation of circulating immunoglobulin.  J Trauma. 1990;  30 830-833
• 50 Bagdade J D, Root R K, Bulger R J. Impaired leukocyte function in patients with poorly controlled diabetes.  Diabetes. 1974;  23 9-15
• 51 Bagdade J D, Stewart M, Walters E. Impaired granulocyte adherence: a reversible defect in host defence in patients with poorly controlled diabetes.  Diabetes. 1978;  27 677-681
• 52 Sima A A, O'Neil S J, Naimark D. et al . Bacterial phagocytosis and intracellular killing by alveolar macrophages in BB rats.  Diabetes. 1988;  37 544-549
• 53 Mowat A, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus.  N Engl J Med. 1971;  284 621-627
• 54 Nolan C M, Beaty H N, Bagdade J D. Further characterization of the impaired bactericidal function of granulocytes in patients with poorly controlled diabetes.  Diabetes. 1978;  27 889-894
• 55 Davidson N J, Sowden J M, Fletcher J. Defective phagocytosis in insulin controlled diabetics: evidence for a reaction between glucose and opsonising proteins.  J Clin Pathol. 1984;  37 783-786
• 56 Drachman R H, Root R K, Wood Jr W B. Studies on the effect of experimental nonketotic diabetes mellitus on antibacterial defence. I. Demonstration of a defect in phagocytosis.  J Exp Med. 1966;  124 227-240
• 57 Garcia M J, McNamara P M, Gordon T, Kannel W B. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up.  Diabetes. 1974;  23 105-111
• 58 Hypertension in Diabetes Study Group . HDS 2: Increased risk of cardio-vascular complications in hypertensive type 2 diabetic patients.  J Hypertens. 1993;  11 319-325
• 59 Hanefeld M, Fischer S, Julius U, Schulze J. et al . Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up.  Diabetologia. 1996;  39 1577-1583
• 60 Hansson L, Zanchetti A, Carruthers S G. et al . Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial.  Lancet. 1998;  351 1755-1762
• 61 UK Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.  BMJ. 1998;  317 703-713
• 62 Adler A I, Stratton I M, Neil H A. et al . Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.  BMJ. 2000;  321 412-419
• 63 Haffner S M, Letho S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.  N Engl J Med. 1998;  339 229-234
• 64 Pyörälä K, Pedersen T R, Kjeksus J, Faergeman O, Olsson A G, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4 S).  Diabetes Care. 1997;  20 614-620
• 65 Goldberg R B, Mellies M J, Sacks F M. et al . Cardiovascular events and their reduction with Pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial.  Circulation. 1998;  98 2513-2519
• 66 Sacks F M, Pfeffer M A, Moyé L A. et al . The effect of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol And Recurrent Events Trial Investigators.  N Engl J Med. 1996;  335 1001-1009
• 67 Sacks F M, Tonkin A M, Craven T. et al . Coronary heart disease in patients with low LDL-cholesterol. Benefit of Pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors.  Circulation. 2002;  105 1424-1428
• 68 Foody J M, Ferdinand F D, Pearce G L, Lytle B W, Cosgrove D M, Sprecher D L. HDL cholesterol level predicts survival in men after coronary artery bypass graft surgery: 20-year experience From The Cleveland Clinic Foundation.  Circulation. 2000;  102 90III-94III
• 69 Campeau L, Hunninghake D B, Knatterud G L. et al . Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors: NHLBI Post Coronary Artery Bypass Graft Clinical Trial.  Circulation. 1999;  99 3241-3247
• 70 American Diabetes Association . Position statement: management of dyslipidemia in adults with diabetes.  Diabetes Care. 2001;  23 558-561
• 71 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol. . Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).  JAMA. 2001;  285 2486-2497
• 72 Tschoepe D, Roesen P. Heart disease in diabetes mellitus: a challenge for early diagnosis and intervention.  Exp Clin Endocrinol Diabetes. 1998;  106 16-24
• 73 Kalter R, Saul C, Weinstein J. Cardiopulmonary bypass. Associated hemostatic abnormalities.  J Thorac Cardiovasc Surg. 1979;  77 428
• 74 Zilla P, Fasol R, Groscurth. et al . Blood platelets in cardiopulmonary bypass operations.  J Thorac Cardiovasc Surg. 1989;  97 379-388
• 75 Mangos G J, Brown M A, Chan W Y, Horton D, Trew P, Withwoth J A. Acute renal failure following cardiac surgery: incidences, outcomes and risk factors.  Aust N Z J Med. 1995;  25 284-289
• 76 Suen W S, Mok C K, Chiu S W. et al . Risk factors for angiology development of acute renal failure (ARF) requiring dialysis in patients undergoing cardiac surgery.  Angiology. 1998;  49 789-800
• 77 Ostermann M E, Taube D, Morgan C J, Evans T W. Acute renal failure following cardiopulmonary bypass: a changing picture.  Intensive Care Med. 2000;  26 565-571
• 78 Brezis M, Rosen S, Epstein F H. The pathophysiological implications of medullary hypoxia.  Am J Kidney Dis. 1989;  13 253-258
• 79 Bryan A G, Bolsin S N, Viana P T, Haloush H. Modification of the diuretic and natriuretic effect of a dopamine infusion by fluid loading in preoperative cardiac surgical patients.  J Cardiothorac Vasc Anes. 1995;  9 158-163
• 80 Baudouin S V, Wiggins J, Keogh B F, Morgan C J, Evans T W. Continuous veno-venous haemofiltration following cardio-pulmonary bypass.  Intensive Care Med. 1993;  19 290-293
• 81 Bellomo R, Ronco C. Continuous hemofiltration in acute renal failure.  Curr Op Anaest. 1996;  9 166-170
• 82 Pozzessere G, Valle E, De Crignis S. et al . Abnormalities of cognitive function in IDDM revealed by P300 event-related potential analysis.  Diabetes. 1991;  40 952-958
• 83 Kramer L, Fasching P, Madl C. et al . Previous episodes of hypoglycemic coma are not associated with permanent cognitive brain dysfunction in IDDM patients on intensive insulin treatment.  Diabetes. 1998;  47 1909-1914
• 84 Mochizuki Y, Oishi M, Hayakawa Y. et al . Improvement of P300 latency by treatment in non-insulin-dependent diabetes mellitus.  Clin Electroencephalogr. 1998;  29 194-196
• 85 Lynn G M, Stefanko K, Reed III J F, Gee W, Nicholas G. Risk factors for stroke after coronary artery bypass.  J Thorac Cardiovasc Surg. 1992;  104 1518-1523
• 86 Newman M F, Wolman R, Kanchuger M. et al . Multicenter preoperative stroke risk index for patients undergoing coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group.  Circulation. 1996;  94 II74-80
• 87 Roach G W, Kanchuger M, Mangano C M. et al . Adverse cerebral outcomes after coronary bypass surgery.  N Engl J Med. 1996;  335 1857-1863
• 88 Smith P, Treasure T, Newman S, Joseph P, Ell P, Schneidau A, Harrison M. Cerebral consequences of cardiopulmonary bypass.  Lancet. 1986;  1 823-825
• 89 Jorgenson H S, Reith J, Nakayama H. et al . Copenhagen Stroke Study. Potentially reversible factors during the very acute phase of stroke and their impact on the prognosis: is there a large therapeutic potential to be explored?.  Cerebrovasc Dis. 2001;  11 207-211
• 90 Weir C J, Murray G D, Dyker A G, Lees K R. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study.  BMJ. 1997;  314 1303-1306